Revolution Medicines, Inc. (RVMD) Bundle
A Brief History of Revolution Medicines, Inc. (RVMD)
Company Overview
Revolution Medicines, Inc. is a precision oncology company headquartered in Redwood City, California. The company focuses on developing novel targeted therapies for RAS-addicted cancers.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Stock Price (as of Q4 2023) |
|---|---|---|---|
| 2022 | $79.4 million | $248.3 million | $11.72 |
| 2023 | $94.2 million | $285.6 million | $8.45 |
Key Pipeline Assets
- RMC-4630: A SHP2 inhibitor for solid tumors
- RMC-5552: A RAS(ON) inhibitor
- RMX-5404: A KRASG12D inhibitor
Clinical Development Status
As of 2024, Revolution Medicines has multiple ongoing clinical trials across various oncology indications.
| Drug Candidate | Clinical Stage | Target Indication |
|---|---|---|
| RMC-4630 | Phase 2 | Solid tumors |
| RMC-5552 | Phase 1/2 | RAS-mutant cancers |
Investor and Funding Information
Total funding raised: $663.4 million through venture capital and public offerings as of 2023.
Institutional Investors
- Fidelity Management & Research
- Vanguard Group
- BlackRock
Research Collaborations
Active research partnerships with Boehringer Ingelheim and Sanofi as of 2024.
A Who Owns Revolution Medicines, Inc. (RVMD)
Major Institutional Shareholders
As of the latest available data, the top institutional shareholders of Revolution Medicines, Inc. include:
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 4,132,280 | 9.52% |
| BlackRock Inc. | 3,890,445 | 8.96% |
| Fidelity Management & Research Company | 2,845,672 | 6.55% |
Insider Ownership
Key insider ownership details include:
- Mark A. Goldsmith - Chairman of the Board, owns 282,352 shares
- Justin Frare - Chief Financial Officer, owns 98,745 shares
- Mark A. Goldsmith (through direct and indirect holdings) owns approximately 1.2% of total outstanding shares
Ownership Structure
Ownership breakdown as of 2024:
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 68.3% |
| Insider Ownership | 3.7% |
| Retail Investors | 28% |
Notable Venture Capital Investors
- ARCH Venture Partners
- Boxer Capital
- OrbiMed Advisors
Public Ownership
Total outstanding shares: 43,450,000
Float (publicly tradable shares): 41,200,000
Revolution Medicines, Inc. (RVMD) Mission Statement
Company Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers.
Financial Performance
| Market Cap (as of January 2024) | $1.02 billion |
| Annual Revenue (2022) | $58.4 million |
| Net Loss (2022) | $246.1 million |
| Cash and Investments (Q3 2023) | $637.1 million |
Research and Development Focus
- Development of precision oncology therapies targeting RAS mutations
- Pipeline of small molecule therapies for solid tumors
- Targeting specific molecular drivers of cancer
Key Pipeline Candidates
| RMC-4630 | SHP2 inhibitor | Phase 2 clinical trials |
| RMC-5552 | KRAS G12D inhibitor | Phase 1/2 clinical trials |
| RMC-6291 | KRAS G12C inhibitor | Phase 1/2 clinical trials |
Strategic Collaborations
- Partnership with Sanofi (signed in 2021)
- Collaboration value: Up to $1.2 billion
- Focus on RAS-targeted therapies
Stock Performance
| Stock Symbol | RVMD |
| 52-Week Low | $6.11 |
| 52-Week High | $22.29 |
| Current Stock Price (January 2024) | $11.47 |
How Revolution Medicines, Inc. (RVMD) Works
Company Overview
Revolution Medicines, Inc. is a precision oncology company founded in 2014 and headquartered in Redwood City, California. The company focuses on developing novel targeted therapies for RAS/MAPK pathway-driven cancers.
Financial Performance
| Financial Metric | 2023 Data |
|---|---|
| Market Capitalization | $854.2 million |
| Total Revenue | $48.3 million |
| Net Loss | $216.7 million |
| Cash and Investments | $442.1 million |
Research and Development Pipeline
- RMC-4630: SHP2 inhibitor in clinical trials for solid tumors
- RMC-5552: Pan-RAS inhibitor targeting multiple RAS mutations
- RMC-6291: G12C specific KRAS inhibitor
Clinical Development Status
| Drug Candidate | Clinical Stage | Target Indication |
|---|---|---|
| RMC-4630 | Phase 2 | Solid tumors |
| RMC-6291 | Phase 1/2 | KRAS G12C mutations |
Key Partnerships
- Collaboration with Sanofi for RAS-targeted therapies
- Strategic research agreement with Genentech
Operational Metrics
As of December 31, 2023, Revolution Medicines employed approximately 250 full-time employees.
How Revolution Medicines, Inc. (RVMD) Makes Money
Revenue Streams
Revolution Medicines, Inc. generates revenue through multiple channels:
- Research and development collaborations
- Licensing agreements
- Potential future product sales
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $86.4 million |
| Collaboration Revenue | $75.2 million |
| Net Loss | $201.1 million |
Key Collaboration Partners
- Genentech
- Sanofi
- Boehringer Ingelheim
Research Pipeline
Primary Focus Areas:
- RAS-targeted precision oncology therapies
- Small molecule drug development
- Targeting cancer mutations
Intellectual Property
Revolution Medicines holds multiple patent applications and issued patents covering their drug candidates and technological platforms.
| Patent Category | Number of Patents |
|---|---|
| Issued Patents | 35 |
| Pending Patent Applications | 22 |
Research and Development Expenses
| Year | R&D Expense |
|---|---|
| 2022 | $182.3 million |
| 2023 | $214.6 million |
Revolution Medicines, Inc. (RVMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.